Fresenius Medical Care reports adjusted EPS for 2023 up 4% to 2.58 euros, as well as adjusted operating income of 1.74 billion, up 15% at constant exchange rates, above the upper limit of its target range.

It highlights a 'successful execution of the turnaround plan, resulting in significant improvements in labor productivity in care delivery and positive pricing in care enablement'.

At almost 19.5 billion euros, sales of the German dialysis specialist remained stable on a reported basis, but rose by 5% at constant exchange rates, driven by favorable business trends.

A dividend of 1.19 euros per share will be proposed for the past year. For 2024, management forecasts continued growth in sales and accelerated growth in operating income.

Copyright (c) 2024 All rights reserved.